Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3 domain and tetratricopeptide repeat-containing protein 1 (SH3TC1) is a large, multi-domain human protein (UniProt Q8TE82) characterized by the presence of SH3 (SRC homology 3) domains and tetratricopeptide repeats (TPR)[1][3]. SH3 domains are small modular domains (~60 amino acids) involved in mediating protein–protein interactions by binding proline-rich motifs, facilitating the assembly of dynamic multiprotein complexes[1][2]. TPR motifs also mediate protein–protein interactions, usually involved in assembling large protein complexes. While the broader family of SH3 domain-containing proteins mediates signal transduction, cell proliferation, and other essential cellular processes, a specific biological or disease role for SH3TC1 itself remains to be elucidated, and the function of SH3TC1 is reported as unclear[7]. No approved drugs are known to interact directly with SH3TC1, and it is not currently recognized as a direct therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SH3 domain and tetratricopeptide repeat-containing protein 1 (SH3TC1).